Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.79 |
| ▸ | MEN1 | O00255 | 5/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | RECQL | P46063 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
| ▸ | GLA | P06280 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | CASP1 | P29466 | 3/20 | 0.77 |
| ▸ | CASP7 | P55210 | 3/20 | 0.77 |
| ▸ | HBB | P68871 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | USP2 | O75604 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.77 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.77 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27818301 | 1.00 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27170416 | 0.91 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27603460 | 0.91 | TOP1 (0.85) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6599316 | 0.91 | TOP1 (0.85) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18251452 | 0.91 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16214743 | 0.91 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23432348 | 0.90 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18251457 | 0.90 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5325716 | 0.90 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27170420 | 0.90 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095785-B1 | SYNTHESIS METHOD OF 9-ALLYLCAMPTOTHECIN DERIVATIVES | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2018-02-07 | — | — | EP | disclosed |
| US-9643975-B2 | Synthesis method of 9-allylcamptothecin derivatives | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD (CN) | 2017-05-09 | — | — | US | disclosed |
| US-9643975-B2 | Synthesis method of 9-allylcamptothecin derivatives | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD (CN) | 2017-05-09 | — | — | US | disclosed |
| US-20160340364-A1 | SYNTHESIS METHOD OF 9-ALLYLCAMPTOTHECIN DERIVATIVES | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2016-11-24 | — | — | US | disclosed |
| US-20160340364-A1 | SYNTHESIS METHOD OF 9-ALLYLCAMPTOTHECIN DERIVATIVES | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2016-11-24 | — | — | US | disclosed |
| EP-3095785-A1 | SYNTHESIS METHOD OF 9-ALLYLCAMPTOTHECIN DERIVATIVES | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2016-11-23 | — | — | EP | disclosed |
| EP-0968213-B1 | ALKYNYL-SUBSTITUTED CAMPTOTHECINS AND PROCESS FOR THEIR PREPARATION | PHARMACIA ITALIA SPA (IT) | 2003-01-22 | — | — | EP | disclosed |
| US-6420379-B1 | ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-07-16 | — | — | US | disclosed |
| US-6211192-B1 | ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-04-03 | — | — | US | disclosed |
| EP-0968213-A1 | ALKYNYL-SUBSTITUTED CAMPTOTHECINS AND PROCESS FOR THEIR PREPARATION | Pharmacia & Upjohn S.p.A. (IT) | 2000-01-05 | — | — | EP | disclosed |
| US-5856333-A | ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-01-05 | — | — | US | disclosed |
| WO-1998035969-A1 | ALKYNYL-SUBSTITUTED CAMPTOTHECINS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-08-20 | — | — | WO | disclosed |
| EP-0777670-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996037496-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340364-A1 | SYNTHESIS METHOD OF 9-ALLYLCAMPTOTHECIN DERIVATIVES | XPOT, HCCS, DHPS | TOP1 24/4885MEN1 242/4885KMT2A 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.